

HC Pat Rev

From: DG/CA

Location: IDC (FMF) FDC

Date: 7/6/05

Tracking #: _____ Week Date: _____

DOC CODE	DOC DATE	MISCELLANEOUS
<input type="checkbox"/> 1449	_____	<input type="checkbox"/> Continuing Data
<input type="checkbox"/> IDS	_____	<input type="checkbox"/> Foreign Priority
<input type="checkbox"/> CLM	_____	<input type="checkbox"/> Document Legibility
<input type="checkbox"/> IIFW	_____	<input type="checkbox"/> Fees
<input type="checkbox"/> SRFW	_____	<input type="checkbox"/> Other
<input checked="" type="checkbox"/> DRW	6/9/04	
<input type="checkbox"/> OATH	_____	
<input type="checkbox"/> 312	_____	
<input type="checkbox"/> SPEC	_____	

BEST AVAILABLE COPY

[RUSH] MESSAGE: Att: Chief Drafts person
Figures 2, 3, 5 & 6 have improper shading. please Rescure.
Thank You
(CP)

[XRUSH] RESPONSE: Corrected Drawings

INITIALS: CBR

NOTE: This form will be included as part of the official USPTO record, with the Response document coded as XRUSH.
REV 10/04




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7





FIG. 8

Fragment	Sequence	SEQ ID NO
A	PKPQRKTKRN TIRRPQDVKE PGGQIVG	23
B	PKPQRQTKRN TNRRPQDVKE PGGQIVG	24
C	PKPQRKTKRN TYRRPQDVKE PGGQIVG	25
D	PKPQRKPNRN TNRRPQDVKE PGGQIVG	26
E	PKPQRQPKRN TPRRPQDVKE PGGQIVG	27
F	PKPQRKTKRN AHRRPQDVKE PGGQIVG	28
G	PKPQKRNRN TNRRPQDVKE PGGQIVG	29
H	PKPQRKTKRN TIRRPQDVKE PGGVIVV	30
I	PKPQRKTERN TNRRPQDVRF SGGQIVG	31
J	PKPKRQTKRN TLRRPKNVKE PAGQIVG	32
K	PKPQRKTKRK AHRRPQDVKE PGGQIVG	33


FIG. 9



* PCR, clone, PCR for sequence confirmation and sequential assembly, express, determine immunoreactivity

FIG. 10

Figure 11



BEST AVAILABLE COPY




FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 16





FIG. 17




Domain 1691-1710 aa (5-1-1)

Domain 1712-1733 aa (5-1-1)

Domain 1921-1940 aa (59)


FIG. 18



* PCR, clone, PCR for sequence confirmation and sequential assembly, express, determine immunoreactivity

FIG. 19

Figure 20






FIG. 21

FIG. 22A





FIG. 22B



	NC Matrix	NS3 Matrix	NS4 Matrix	NS4 Mosaic
No. of anti-HCV sera tested	182	182	182	182
No. of positive sera	172	179	158	178
Percent positive	94.5%	98.4%	86.8%	97.8%

FIG. 23

4811




FIG. 24A

6214




FIG. 24B

4812




FIG. 24C

4813





FIG. 24D

Figure 25



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.